News | Antiplatelet and Anticoagulation Therapies | January 17, 2017

Changes to Hospital Electronic Health Records Could Improve Care of Warfarin Patients

Study finds switching from paper records greatly improved physician-patient communication on medication therapy guidelines

electronic health records, EHR, warfarin therapy management, University of Missouri Health Care, blood thinner

January 17, 2017 — Warfarin is a commonly prescribed blood thinner used to prevent harmful blood clots. However, the drug requires frequent monitoring, daily dosing and can result in serious negative effects when mixed with vitamin K, a vitamin commonly found in vegetables such as lettuce or broccoli. Now, a new study from University of Missouri Health Care has found that using electronic health records (EHR) can improve the care patients receive after they leave the hospital and eliminate potential confusion among care providers and pharmacists.

“Previous research indicates that adverse effects of warfarin accounted for 33 percent of annual emergency hospitalizations for patients 65 or older in the United States,” said Margaret Day, M.D., a primary care physician and medical director at MU Health Care’s Family Medicine-Keene Clinic. “At MU Health Care, we designed the Outpatient Warfarin Management Order record in response to The Joint Commission’s call for institutions to reduce possible patient harm associated with the use of warfarin."

Day said that before the intervention, physicians would give patients warfarin management plans on paper forms, which made it difficult for providers to obtain that information later. Paper forms also sometimes caused confusion among pharmacists, physicians and patients since the warfarin plans could change frequently, according to Day.

MU Health Care currently uses an EHR that generates a comprehensive health summary for each admitted patient. Day said that her team found the discharge summary to be a valuable tool to communicate the key elements needed for patients and health providers to manage warfarin therapy.

“The information entered is visible to the patients and their community healthcare providers,” Day said. “In addition, the record also coordinates communication to pharmacy services for any dosage updates.”

Before implementing the new record, Day’s team found that 42 percent of patients’ discharge charts included key elements for discharging patients on warfarin. After the intervention, the team found that percentage nearly doubled, to 78 percent. In addition, physicians and pharmacists who used the new record were surveyed.

“Of the 28 physicians and pharmacists who took part in the survey, 61 percent said that the new warfarin order was user-friendly and accessible,” Day said.

Day said that this study demonstrates the EHR’s potential value in assisting with warfarin or anticoagulation therapy between outpatient and inpatient settings and across multiple providers. In addition, Day said the new process not only provides notification about the transition care to patients’ referring health providers in their communities, but also facilitates collaborative care with pharmacies.

The project, “Improving Transitions of Care for Hospitalized Patients on Warfarin,” was published in The Joint Commission Journal on Quality and Patient Safety.

For more information: www.jcrinc.com

Related Content

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies| December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies| November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies| November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
Overlay Init